Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man

Pietro Amedeo Modesti, Alberto Fortini, Loredana Poggesi, Maria Boddi, Rosanna Abbate, Gian Franco Gensini

Research output: Contribution to journalArticlepeer-review

Abstract

Platelet sensitivity to PGI2 and platelet PGI2 receptors were investigated in eight subjects with peripheral artery disease (stage IV according to Fontaine) treated for 14 consecutive days with six hour iv infusion of Iloprost (Schering, FRG) 2 ng/Kg/min. Platelet studies were performed on the 1st, the 2nd, the 7th and the 14th day of therapy, immediately before infusion (between 8.00 and 9.00 a.m.), at the end and 6 and 18 hours (the following morning) after the end of the infusion. Platelet sensitivity to PGI2 was assessed by determining the PGI2 inhibitory dose 50(ID 50) on platelet aggregation induced by 5 μM ADP. PGI2 platelet receptors were investigated by a direct radioligand binding assay. PGI2 ID 50 after the infusion was significantly higher than that at baseline(p

Original languageEnglish
Pages (from-to)663-669
Number of pages7
JournalThrombosis Research
Volume48
Issue number6
DOIs
Publication statusPublished - Dec 15 1987

Keywords

  • down-regulation
  • Iloprost
  • prostacyclin
  • receptor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Fingerprint Dive into the research topics of 'Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man'. Together they form a unique fingerprint.

Cite this